Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Flumazenil kinetics in the elderly

G Roncari1, U Timm, M Zell

  • 1Department of Clinical Research, F. Hoffmann-La Roche, Basel, Switzerland.

European Journal of Clinical Pharmacology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MSG.

ESA bulletin. Bulletin ASE. European Space Agency·2003
Same author

High-throughput quantification of drugs and their metabolites in biosamples by LC-MS/MS and CE-MS/MS: possibilities and limitations.

Therapeutic drug monitoring·2002
Same author

Piperidine renin inhibitors: from leads to drug candidates.

Farmaco (Societa chimica italiana : 1989)·2001
Same author

Determination of the oral platelet aggregation inhibitor Sibrafiban in rat, dog, and human plasma utilising HPLC-column switching combined with turbo ion spray single quadrupole mass spectrometry.

Journal of pharmaceutical and biomedical analysis·2000
Same author

Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.

British journal of clinical pharmacology·1999
Same author

Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects.

British journal of clinical pharmacology·1998
Same journal

Efficacy and safety of Ensitrelvir in COVID-19 patients: a systematic review and meta-analysis with focus on viral clearance and RNA change.

European journal of clinical pharmacology·2026
Same journal

Comparing National Health Technology Assessment approaches and the new European Joint Clinical Assessment framework: The case of onco-hematological medicines.

European journal of clinical pharmacology·2026
Same journal

The efficacy of letrozole in the medical management of ectopic pregnancy: a systematic review and meta-analysis.

European journal of clinical pharmacology·2026
Same journal

Detection of intravenous drug physicochemical incompatibilities in clinical practice: e-Harvis compared to reference tools.

European journal of clinical pharmacology·2026
Same journal

Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment.

European journal of clinical pharmacology·2026
Same journal

Critical analysis of digitalis glycosides: declining use but increasing poison-center exposure cases for digitoxin.

European journal of clinical pharmacology·2026
See all related articles

Flumazenil, a medication used to reverse benzodiazepine effects, showed similar absorption and disposition in both young and elderly adults. This suggests aging does not significantly alter how the body processes flumazenil.

Area of Science:

  • Pharmacology
  • Geriatric Medicine
  • Clinical Pharmacology

Background:

  • Flumazenil is a selective benzodiazepine receptor antagonist.
  • Understanding age-related pharmacokinetic differences is crucial for drug dosing.
  • Previous studies on flumazenil pharmacokinetics in the elderly are limited.

Purpose of the Study:

  • To investigate the impact of aging on the absorption and disposition of flumazenil.
  • To compare flumazenil pharmacokinetics in healthy young and elderly volunteers.

Main Methods:

  • An open-label, randomized, two-way crossover study.
  • Administration of single intravenous (2 mg) and oral (30 mg) doses of flumazenil.
  • Plasma sampling and assay of intact flumazenil in healthy young (n=6) and elderly (n=12) volunteers.

Related Experiment Videos

Main Results:

  • Flumazenil was well-tolerated in both age groups, with dizziness and headache as main side effects.
  • Intravenous flumazenil showed similar volume of distribution, clearance, and half-life between young and elderly groups.
  • Oral flumazenil exhibited comparable peak plasma concentrations (Cmax) and absolute bioavailability between age groups.

Conclusions:

  • Aging does not significantly affect the absorption and disposition of flumazenil.
  • The pharmacokinetic profile of flumazenil is consistent across different age groups.
  • This supports the use of standard flumazenil dosing in both young and elderly populations.